Supriya Lifescience Limited receives CEP from EDQM for API

The European Directorate for the Quality of Medicines and HealthCare (EDQM) has granted Certification of Suitability (CEP) for Diphenhydramine Hydrochloride, API in AntiHistamine therapy.

This will be an added advantage for Supriya Lifescience Ltd. in the European market. Global demand for Diphenhydramine Hydrochloride is 1850 tons, of which major demand is in the regulated markets.

Source : Equity Bulls

Keywords

EDQM CertificationofSuitability DiphenhydramineHydrochloride API AntiHistamineTherapy